Knowing when ocular findings call for specialist review, choosing the right animal model, and matching species to program type are foundational decisions in ophthalmic drug development. In this series, Dr. Chris Murphy, board certified veterinary ophthalmologist, and CEO of OSOD, a MERIT Company, walks through what experienced teams rely on to get it right.
For any ophthalmic drug program, one practical question ends up shaping the entire nonclinical plan: for this program, with this route of delivery, which species actually belongs in the study protocol? The answer varies more than newcomers often expect, and it hinges less on convention...
Before an ophthalmic drug candidate reaches its first nonclinical study, someone has to answer a deceptively simple question: which animal do we test it in? The answer depends on where the drug will be delivered, how it will be dosed, and how closely the model's...
Ocular findings have a way of showing up uninvited, and when they do, the quality of the eye exam behind that finding can determine whether a program moves forward or stalls....